Annual Report

Overview

The report highlights final Phase 1 ovarian-cancer results, including a 10% peritoneal recurrence rate at 24 months, and continued Phase 2 development. It records the BerGenBio merger and NOK 130 million equity financing, which strengthened the company's financial platform and runway. The report also describes CSR principles incorporated into the Code of Conduct and outlines working-environment, health-and-safety, and environmental practices.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Language: English
Pages
File size

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services